SITC 2017 Abstract Titles – Regular Oral Presentations

The following is a list of abstracts accepted for oral presentation. To search for abstract content based on keywords, select CTRL+F on your keyboard (or Command+F if you're using a Mac) and type a keyword to search for abstracts related to that keyword.

#

Abstract Category

Title

Authors

Affiliations

Keywords

O1

Biomarkers and Immune Monitoring

Identification of unique neoantigen qualities in long-term pancreatic cancer survivors.

Vinod Balachandran1, Marta Luksza2, Julia N. Zhao1, Vladimir Makarov1, John Alec Moral1, Romain Remark3, Brian Herbst1, Gokce Askan1, Umeshkumar Bhanot1, Yasin Senbabaoglu1, Danny Wells4, Charles Ian Ormsby Cary4, Olivera Grbovic-Huezo1, Marc Attiyeh1, Benjamin Medina1, Jennifer Zhang1, Jennifer Loo1, Joseph Saglimbeni1, Mohsen Abu-Akeel1, Roberta Zappasodi1, Nadeem Riaz1, Martin Smoragiewicz5, Olca Basturk1, Mithat Gönen1, Arnold J. Levine2, Peter J. Allen1, Douglas T. Fearon6, Miriam Merad3, Sacha Gnjatic3, Christine Iacobuzio-Donahue1, Jedd Wolchok1, Ronald DeMatteo7, Benjamin Greenbaum8, Taha Merghoub1, Steven Leach1

1Memorial Sloan Kettering Cancer Center, New York, NY, USA2Institute for Advanced Study, Princeton, NJ, USA3Icahn School of Medicine at Mount Sinai, New York, NY, USA4Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA5University of Cambridge, Cambridge, United Kingdom6Cold Spring Harbor, Cold Spring Harbor, NY, USA7University of Pennsylvania, Philadelphia, PA, USA8Tisch Cancer Institute, New York, NY, USA

Neoantigens | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Bioinformatics | Immune contexture | Biomarkers | Clinical study | Tumor antigens | Surgery

O2

Biomarkers and Immune Monitoring

Predictive biomarkers for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Priyanka Subrahmanyam1, Zhiwan Dong2, Daniel Gusenleitner2, Anita Giobbie-Hurder2, Mariano Severgnini2, Jun Zhou2, Michael Manos2, Holden Maecker1, F. Stephen Hodi2

1Stanford University, Stanford, CA, USA2Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Immune monitoring | Biomarkers | Checkpoint blockade

O3

Biomarkers and Immune Monitoring

Combining immunophenomics with a gene expression panel for improved prostate cancer recurrence prediction

Nathalie Harder1, Harald Hessel2, Maria Athelogou1, Alexander Buchner2, Christian Stief2, Thomas Kirchner2, Günter Schmidt1, Ralf Huss1

1Definiens AG, Munich, Germany2Ludwig-Maximilians-University Munich, Munich, Germany

Bioinformatics | Biomarkers | Gene expression | Immune contexture | Immunoscore | Systems biology | T cell | Tumor microenvironment | Tumor infiltrating lymphocytes (TILs)

O4

Biomarkers and Immune Monitoring

Clinical Activity of Adenosine 2A Receptor (A2AR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation

Andrew Hotson1, John Powderly2, Leisha Emens3, Patrick Forde3, Matthew Hellman4, Lawrence Fong5, Ben Markman6, Brett Hughes7, Jonathan Goldman8, Mario Sznol9, Daruka Mahadevan10, Shivaani Kummar11, Joshua Brody12, Philip Bonomi13, Jason Luke14, Matthew Riese15, Taofeek Owonikoko16, Sherene Loi17, Amy Wiese18, Robert Doebele19, James Lee20, Chunyan Gu21, Stephen Willingham21, Ginna Laport21, Richard Miller21, Ian McCaffery21

1Corvus Pharmaceuticals, Redwood City, CA, USA2Carolina BioOncology Institute, Huntersville, NC, USA3Johns Hopkins University, Baltimore, MD, USA4Memorial Sloan Kettering Cancer Center, New York City, NY, USA5University of California, San Francisco, San Francisco, CA, USA6Monash Medical Centre, Clayton, Australia7Royal Brisbane and Women’s Hospital, Herston, Australia8University of California, Los Angeles, Los Angeles, CA, USA9Yale University School of Medicine, New Haven, CT, USA10University of Arizona, Tucson, AZ, USA11Stanford University School of Medicine, Stanford, CA, USA12Icahn School of Medicine at Mount Sinai, New York City, NY, USA13Rush University Medical Center, Chicago, IL, USA14University of Chicago Medical Center, Chicago, IL, USA15Medical College of Wisconsin, Milwaukee, WI, USA16Emory University Hospital, Atlanta, GA, USA17Peter MacCallum Cancer Centre, Melbourne, Australia18Wayne State University, Detroit, MI, USA19University of Colorado Anschutz Medical Campus, Aurora, CO, USA20University of Pittsburgh, Pittsburgh, PA, USA21Corvus Pharmaceuticals, Burlingame, CA, USA

Biomarkers | Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Clinical trial

O5

Cancer Vaccines

A dendritic cell targeting NY-ESO-1 vaccine significantly augments early and durable immune responses in melanoma patients pretreated with human Flt-3 Ligand

Nina Bhardwaj1, Philip Friedlander2, Anna Pavlick3, Marc Ernstoff4, Brian Gastman5, Brent Hanks6, Mark Albertini7, Jason Luke8, Michael Yellin9, Tibor Keler9, Thomas Davis9, Laura Vitale9, Ana Blazquez10, Chihiro Morishima11, Patrick Danaher12, Sarah Warren12, Bob Salim13, Bruce Hess11, Leonard D'Amico11, Lisa Lundgren14, Nora Disis11, Martin Cheever14, Steven Fling14

1Icahn School of Medicine at Mount Sinai, New York, NY, USA2Mount Sinai Beth Israel, New York, NY, USA3NYU Lagone Medical Center, New York, NY, USA4Roswell Park Cancer Institute, Buffalo, NY, USA5Cleveland Clinic, Cleveland, OH, USA6Duke, Durham, NC, USA7University of Wisconsin, Madison, WI, USA8University of Chicago Medicine, Chicago, IL, USA9Celldex Therapeutics, Needham, MA, USA10Mount Sinai, New York, NY, USA11University of Washington, Seattle, WA, USA12Nanostring Technologies, Seattle, WA, USA13Axio Research, Seattle, WA, USA14Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Antigen presenting cells | Dendritic cell | Myeloid cells | Tumor antigens | Immune monitoring | Gene expression | T cell | Vaccine | Immune adjuvant | Monocyte/Macrophage

O6

Cellular Metabolism and Antitumor Immunity

Re-educating macrophage through glutamine metabolism-mediated metabolic and epigenetic reprogramming

Ping-Chih Ho1

1University of Lausanne, Epalinges, Switzerland

Myeloid cells | Immune suppression | Metabolism | Monocyte/Macrophage | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment

O7

Cellular Metabolism and Antitumor Immunity

Early FDG-PET response correlates with dose and efficacy in patients with microsatellite stable mCRC treated with carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody plus atezolizumab

Said Bouseida1, Federico Sandoval1, Daniel Sabanes Bove2, Vaios Karanikas3, Abiraj Keelara1, Tapan Nayak1, Jose Saro3

1Roche Innovation Center Basel, Basel, Switzerland2F. Hoffmann-La Roche Ltd., Basel, Switzerland3Roche Innovation Center Zurich, Zurich, Switzerland

Solid tumors | T cell | Biomarkers | Tumor antigens | Checkpoint blockade | Clinical study | Antibody

O8

Cellular Metabolism and Antitumor Immunity

Lactic Acid as a Mediator of Metabolic Symbiosis Between Regulatory T cells and the Tumor Microenvironment

McLane Watson1, Ryan Whetstone1, Rahul Deshpande1, Ashely Menk1, Nicole Scharping1, Brett Morrison2, Stacy Gellhaus Wendell1, Greg Delgoffe1

1University of Pittsburgh, Pittsburgh, PA, USA2Johns Hopkins, Baltimore, MD, USA

Regulatory T cell (Treg) | Tumor microenvironment | Checkpoint blockade | Metabolism | T cell | Tumor infiltrating lymphocytes (TILs) | Tumor evasion

O9

Cellular Therapy Approaches

Transcriptional approach to understanding the role of tonic signaling and co-stimulation in CAR T cells

Angela Boroughs1, Nemanja D. Marjanovic2, Ana P. Castano3, Robert Morris3, Livnat Jerby2, Felipe Bedoya3, Aviv Regev2, Marcela V. Maus3

1Massachusetts General Hospital, Harvard University, Boston, MA, USA2Broad Institute of Harvard and MIT, Cambridge, MA, USA3Massachusetts General Hospital, Boston, MA, USA

Adoptive immunotherapy | Bioinformatics | Costimulation | T cell lineages | T cell | Gene expression | Cytokine | CAR T cells

O10

Cellular Therapy Approaches

Gamma secretase inhibition increases recognition of multiple myeloma by BCMA-specific chimeric antigen receptor modified T cells

Tyler Hill1, Margot Pont1, Joe Abbott1, Jessica Kelliher1, Alexander Salter1, Steven Liu1, Damian Green1, Stanley Riddell1

1Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Adoptive immunotherapy | CAR T cells | Targeted therapy | Tumor antigens

O11

Clinical Trials (Completed)

DNA vaccine with PD-1 blockade elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Douglas McNeel1, Jens Eickhoff1, Robert Jeraj1, Mary Jane Staab1, Jane Straus1, Ellen Wargowski1, Matthew Scarpelli1, Glenn Liu1

1University of Wisconsin, Madison, WI, USA

Checkpoint blockade | Clinical trial | Vaccine

O12

Clinical Trials (Completed)

Immune and Tumor Responses to Human IL-10 (AM0010, Pegilodecakin) alone or in combination with immune checkpoint blockade

Aung Naing1, Deborah J. Wong2, Jeffrey R. Infante3, Kyriakos Papadopoulos4, Raid Aljumaily5, W. Michael Korn6, Jeffrey G. Schneider7, Manish Patel8, Karen A Autio9, Gerald S. Falckook10, Nashat Y. Gabrail11, Bianca Rojo12, Navneet Ratti12, Scott McCauley12, Annie Hung12, Peter Van Vlasselaer12, Gail L. Brown12, Edward B. Garon2, Nizar M. Tannir1, Martin Oft12

1MDACC, Houston, TX, USA2UCLA, Los Angeles, CA, USA3SCRI, Nashville, TN, USA4START, San Antonio, TX, USA5OUHSC, OKLAHOMA CITY, OK, USA6UCSF, San Francisco, CA, USA7Winthrop University Hospital, Mineola, NY, USA8Florida Cancer Specialists, Sarasota, FL, USA9MSKCC, New York, NY, USA10Sarah Cannon at HealthOne, Denver, CO, USA11Gabrail Cancer Center, Canton,, OH, USA12ARMO BioSciences, Redwood City, CA, USA

Cytokine | T cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Immunoscore | Neoantigens | Checkpoint blockade | Tumor microenvironment

O13

Clinical Trials (In Progress)

A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors

Glen J. Weiss1, Jason J. Luke2, Gerald Falchook3, Zeynep Eroglu4, Judy Wang5, Erika Hamilton6, J. Randolph Hecht7, Patricia LoRusso8, Joseph Paul Eder8, Lorraine Hughes9, Jing Wang9, Kelli Running9, Kristen McEachern9, Dmitri Bobilev9, Antoni Ribas7

1Western Regional Medical Center Inc., Goodyear, AZ, USA2University of Chicago Medical Center, Chicago, IL, USA3Sarah Cannon Research Institute at HealthONE, Denver, CO, USA4H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA5Florida Cancer Specialists, Sarasota, FL, USA6Tennessee Oncology, PLLC, Nashville, TN, USA7University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA8Smilow Cancer Hospital at Yale - New Haven, New Haven, CT, USA9TESARO Inc., Waltham, MA, USA

Antibody | Checkpoint blockade | Clinical trial | T cell | Targeted therapy

O14

Clinical Trials (In Progress)

Initial results from phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with NSCLC refractory or resistant to prior anti–PD-1/anti–PD-L1 agents

Fabrice Barlesi1, Nicolas Isambert2, Enriqueta Felip3, Byoung Chul Cho4, Dae Ho Lee5, Julio Peguero6, Guy Jerusalem7, Nicolas Penel8, Esma Saada-Bouzid9, Pilar Garrido10, Christoph Helwig11, Isabelle Dussault12, Laureen Ojalvo12, James Gulley13

1Aix-Marseille University, Livon, France2Centre Georges-François Leclerc, Dijon Cedex, France3Vall D’Hebron University Hospital, Barcelona, Spain4Yonsei Cancer Center, Seoul, Republic of Korea5University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea6Memorial Hermann Texas Medical Center, Houston, TX, USA7CHU Liege and Liege University, Liege, Belgium8Centre Oscar Lambret, Lille, France9Centre Antoine Lacassagne, Nice, France10University Hospital Ramón y Cajal, Madrid, Spain11Merck KGaA, Darmstadt, Germany12EMD Serono, Billerica, MA, USA13National Cancer Institute, Bethesda, MD, USA

Checkpoint blockade | Clinical study | Antibody | Clinical trial | Immune suppression | Tumor microenvironment | Targeted therapy | Tumor evasion

O15

Clinical Trials (In Progress)

Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: preliminary findings

Sangeetha M. Reddy1, Rodabe N. Amaria1, Christine N. Spencer1, Michael Tetzlaff1, Alexandre Reuben1, Miles Andrews1, Linghua Wang1, Scott Woodman1, Haifeng Zhu1, Jorge Blando1, Luis Vence1, Shaojun Zhang1, Hong Jiang1, Vancheswaran Gopalakrishnan1, Courtney Hudgens1, Khalida Wani1, Hussein Tawbi1, Adi Diab1, Isabella Glitza1, Sapna Patel1, Wen-Jen Hwu1, Michael Wong1, Patrick Hwu1, Janice Cormier1, Anthony Lucci1, Richard Royal1, Jeffrey E. Lee1, Lauren Simpson1, Elizabeth M. Burton1, Jeffrey E. Gershenwald1, Merrick Ross1, James Allison1, Padmanee Sharma1, Michael Davies1, Jennifer Wargo1

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Immune monitoring | Clinical study | Checkpoint blockade | Biomarkers | Tumor microenvironment

O16

Combination Therapy (IO/IO, IO/Standard of Care, IO/Other)

A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC)

Funda Meric-Bernstam1, Michael Gordon2, Scott Tykodi3, Elaine Lam4, Ulka Vaishampayan5, Jorge Chaves6, Petros Nikolinakos7, Alice Fan8, Richard Lee9, David McDermott10, Geoffrey Shapiro11, Leena Gandhi12, Hussein Tawbi1, Shailender Bhatia3, Lucas Muigai13, Yonchu Jenkins13, Sam Whiting13, Martin Voss14

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA2Pinnacle Oncology Hematology, Scottsdale, AZ, USA3Seattle Cancer Care Alliance, Seattle, WA, USA4University of Colorado School of Medicine, Aurora, CO, USA5Karmanos Cancer Center, Detroit, MI, USA6Northwest Medical Specialties, Tacoma, WA, USA7University Cancer & Blood Center, Athens, GA, USA8Stanford University Medical Center, Stanford, CA, USA9Massachusetts General Hospitcal, Boston, MA, USA10Beth Israel Deaconess Medical Center, Boston, MA, USA11Medical Oncology, Boston, MA, USA12NYU Medical Oncology Associates, New York, NY, USA13Calithera Biosciences, Inc., South San Francisco, CA, USA14Memorial Sloan Kettering Cancer Center, New York, NY, USA

Checkpoint blockade | Clinical trial | Immune suppression | Metabolism | Solid tumors | Targeted therapy | T cell | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | Tumor evasion

O17

Combination Therapy (IO/IO, IO/Standard of Care, IO/Other)

OX40 T-cell costimulatory agonist BMS-986178 alone or in combination with nivolumab in patients with advanced solid tumors: initial phase 1 results

Anthony J. Olszanski1, Ignacio Melero2, Michael Ong3, Anna Spreafico4, Kimberley Heinhuis5, Richard Carvajal6, Maria Ochoa de Olza7, Quincy Chu8, Anke Klippel9, Yun Shen9, Yan Feng9, Bryan Barnhart9, Alan Korman9, Michael Quigley9, Paula M. Fracasso9, Praveen Aanur9, Martin Gutierrez10

1Fox Chase Cancer Center, Philadelphia, PA, USA2Clinica Universidad de Navarra, Pamplona, Spain3The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada4Princess Margaret Cancer Centre, Toronto, ON, Canada5The Netherlands Cancer Institute, Amsterdam, Netherlands6Columbia University Medical Center, New York, NY, USA7Vall d'Hebron University Hospital, Barcelona, Spain8Cross Cancer Institute, University of Alberta/Alberta Health Services, Edmonton, AB, Canada9Bristol-Myers Squibb, Princeton, NJ, USA10Hackensack University Medical Center, Hackensack, NJ, USA

Biomarkers | Checkpoint blockade | Clinical trial | Costimulation | Regulatory T cell (Treg) | Solid tumors | T cell | Tumor microenvironment

O18

Combination Therapy (IO/IO, IO/Standard of Care, IO/Other)

TLR9 agonist harnesses innate immunity to drive tumor-infiltrating T cell expansion in distant lesions in a phase 1/2 study of intratumoral IMO-2125+ipilimumab in anti-PD1 refractory melanoma patients

Cara Haymaker1, Marc Uemura1, Wen-Jen Hwu1, Ravi Murthy1, Marihella James1, Ankit Bhatta1, Salah Eddine Bentebibel1, Julie Brevard2, James Geib3, Kathryn Lipford2, Mark Cornfeld3, Srinivas Chunduru3, Cassian Yee1, Scott Woodman1, Rodabe Amaria1, Sapna Patel1, Hussein Tawbi1, Isabella Glitza Oliva1, Michael Davies1, Willem Overwijk1, Patrick Hwu1, Chantale Bernatchez1, Adi Diab1

1University of Texas MD Anderson Cancer Center, Houston, TX, USA2Idera Pharmaceuticals Inc., Cambridge, MA, USA3Idera Pharmaceuticals, Inc., Exton, PA, USA

Dendritic cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Immune adjuvant | Clinical trial | Immune monitoring | TLR | Immune contexture

O19

Combination Therapy (IO/IO, IO/Standard of Care, IO/Other)

ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)

Leena Gandhi1, Melissa L. Johnson2, Mateusz Opyrchal3, Suresh Ramalingam4, Pasi Janne5, Abraham Chachoua1, Peter Ordentlich6, Susan Brouwer6, Serap Sankoh6, Emmett Schmidt7, Michael L. Meyers8, Matthew Hellmann9

1NYU Langone Medical Center, New York, NY, USA2Sarah Cannon Research Institute, Nashville, TN, USA3Roswell Park Cancer Institute, Buffalo, NY, USA4Winship Cancer Institute, Emory University, Atlanta, GA, USA5Dana Farber Cancer Institute, Boston, MA, USA6Syndax Pharmaceuticals, Inc., Waltham, MA, USA7Merck & Co., Inc., Kenilworth, NJ, USA8Syndax Pharmaceuticals, Inc., New York, NY, USA9Memorial Sloan Kettering Cancer Center, New York, NY, USA

Checkpoint blockade | Clinical study | MDSC

O20

Combination Therapy (IO/IO, IO/Standard of Care, IO/Other)

Pivot-02: Preliminary safety, efficacy and biomarker results from the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic solid tumors

Adi Diab1, Nizar Tannir1, Daniel Cho2, Vali Papadimitrakopoulou1, Chantale Bernatchez1, Cara Haymaker1, Salah Eddine Bentebibel1, Brendan Curti3, Michael Wong1, Scott Tykodi4, Igor Puzanoff5, Ira Smalberg5, Ivan Gergel6, Mary Tagliaferri6, Jonathan Zalevsky6, Ute Hoch6, Sandra Aung6, Michael Imperiale6, Wendy Clemens7, Harriet Kluger8, Michael Hurwitz8, Patrick Hwu1, Mario Sznol8

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA2NYU Medical Oncology Associates, New York, NY, USA3Providence Cancer Center and Earle A. Chiles Research Institute, Portland, OR, USA4University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA5Roswell Park Cancer Institute, Buffalo, NY, USA6Nektar Therapeutics, San Francisco, CA, USA7Bristol-Myers Squibb, Lawrence Township, NJ, USA8Yale School of Medicine, New Haven, CT, USA

Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | NK/NK T cell | Cytokine | Clinical trial | Tumor microenvironment | Regulatory T cell (Treg) | Checkpoint blockade | Biomarkers

O21

Combination Therapy (IO/IO, IO/Standard of Care, IO/Other)

Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma

Michael Postow1, James Larkin2, Jedd D. Wolchok1, Vanna Chiarion-Sileni3, F. Stephen Hodi4, Piotr Rutkowski5, Jean-Jacques Grob6, Kenneth Grossmann7, Dirk Schadendorf8, Jason Chesney9, Michael Smylie10, Andrew Hill11, Caroline Robert12, Anna C. Pavlick13, John Haanen14, Grant A. McArthur15, David McDermott16, Sheena Demelo17, Rafia Bhore17, Rene Gonzalez18

1Memorial Sloan Kettering Cancer Center, New York, NY, USA2Royal Marsden Hospital, London, United Kingdom3Oncology Institute of Veneto IRCCS, Padova, Italy4Dana-Farber Cancer Institute, Boston, MA, USA5Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland6Hospital de la Timone, Marseille, France7Huntsman Cancer Institute, Salt Lake City, UT, USA8Department of Dermatology, University of Essen, Essen, Germany9James Graham Brown Cancer Center, Louisville, KY, USA10Cross Cancer Institute, Edmonton, AB, Canada11Tasman Oncology Research, Southport Gold Coast, Australia12Institut Gustave-Roussy, Villejuif, France13NYU Medical Oncology Associates, New York, NY, USA14Netherlands Cancer Institute, Amsterdam, Netherlands15Peter MacCallum Cancer Centre, Melbourne, Australia16Beth Israel Deaconess Medical Center, Boston, MA, USA17Bristol-Myers Squibb, Princeton, NJ, USA18University of Colorado Cancer Center, Denver, CO, USA

Checkpoint blockade | Clinical trial | Solid tumors

O22

Combination Therapy (IO/IO, IO/Standard of Care, IO/Other)

Antibody-mediated neutralization of soluble MIC significantly enhances response to CTLA4 blockade and reduces therapy-induced colitis

Jennifer Wu1, Jinyu Zhang2

1Northwestern University, Chicago, IL, USA2Medical University of South Carolina, Charleston, SC, USA

Tumor microenvironment | Checkpoint blockade | Immune toxicity | Antibody | Solid tumors | Tumor evasion | Costimulation

O23

Emerging Models and Imaging

Multiplex three-dimensional optical mapping of tumor immune microenvironment

Steve Seung-Young Lee1, Vytautas P. Bindokas1, Stephen J Kron1

1University of Chicago, Chicago, IL, USA

Tumor infiltrating lymphocytes (TILs) | T cell | Solid tumors | Biomarkers | Immune contexture | Tumor microenvironment | Targeted therapy | Antibody | Checkpoint blockade | Radiotherapy

O24

Immune Modulation, Cytokines, and Antibodies

First-in-human study with intratumoral administration of a CD40 agonistic antibody: preliminary results with ADC-1013/JNJ-64457107 in advanced solid malignancies

Peter Ellmark1, Sandra Irenaeus2, Dorte Nielsen3, Adnan Deronic1, Niina Veitonmäki1, Per Norlén1, Camilla Wennersten1, Jeffrey Yachnin4, Gustav Ullenhag2

1Alligator Bioscience, Lund, Sweden2Uppsala University, Uppsala, Sweden3University of Copenhagen, Herlev, Denmark4Karolinska Institutet and University Hospital, Stockholm, Sweden

Costimulation | Dendritic cell | Clinical study | Antibody | Clinical trial | T cell

O25

Immune Modulation, Cytokines, and Antibodies

Phase I trial of IL-15 superagonist ALT-803 (IL-15N72D:IL-15RαSu/IgG1 Fc complex) in advanced solid tumors: tolerability and correlates of activity

Kim Margolin1, Chihiro Morishima2, Martin A. Cheever2, Andreanne Lacroix2, Steve Fling2, Shernan Holtan3, Monica Jones4, Judy Kaiser2, Sylvia Lee5, Jeffrey S. Miller3, Peter Rhode4, Amy Rock4, Ann W. Silk6, Vamsi Velcheti7, Hing C. Wong4, Marc S. Ernstoff8

1City of Hope, Duarte, CA, USA2Fred Hutchinson Cancer Research Center, Seattle, WA, USA3University of Minnesota, Minneapolis, MN, USA4Altor BioScience, Miramar, FL, USA5University of Washington, Seattle, WA, USA6Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA7Cleveland Clinic, Cleveland, OH, USA8Roswell Park Cancer Center, Buffalo, NY, USA

Clinical study | Clinical trial | Cytokine | Immune adjuvant | Immune toxicity | Immune monitoring | T cell

O26

Mechanisms of Resistance to Immunotherapy

Metabolic adaptations establish immunotherapy resistance in melanoma

Ashvin R. Jaiswal1, Shivanand Pudakalakatti2, Prasanta Dutta2, Liu Arthur2, Todd Bartkowiak2, Casey Ager2, Cristina Ivan2, Michael A Davies2, James P Allison2, Richard Eric Davis2, Jennifer Wargo2, Pratip K Bhattacharya2, David Hong2, Michael A. Curran2

1UT MD Anderson Cancer Center, Houston, TX, USA2The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Myeloid cells | Tumor microenvironment | Biomarkers | Checkpoint blockade | Gene expression | Immune suppression | Metabolism | Tumor infiltrating lymphocytes (TILs) | Tumor evasion | Vaccine

O27

Mechanisms of Resistance to Immunotherapy

Single cell RNA sequencing reveals mechanisms of Merkel Cell Carcinoma escape from intense pressure of T Cell immunotherapy

Kelly Paulson1, Valentin Voillet1, Maurizio Perdicchio1, Daniel Hunter1, William Valente1, Felecia Wagener1, Samson Koelle2, Candice Church3, Natalie Vandeven3, Hannah Thomas3, Aric Colunga3, David Koelle3, Cassian Yee4, Rima Kulikauskas3, Robert Pierce1, Philip Greenberg1, Shailender Bhatia1, Jason Bielas1, Raphael Gottardo1, Paul Nghiem3, Aude Chapuis1

1Fred Hutchinson Cancer Research Center, Seattle, WA, USA2Fred Hutchinson Cancer Research Division, Seattle, WA, USA3University of Washington, Seattle, WA, USA4MD Anderson, Houston, TX, USA

Adoptive immunotherapy | Tumor antigens | T cell | Tumor evasion | Biomarkers | Clinical study | Immune monitoring

O28

Mechanisms of Resistance to Immunotherapy

Functional Correlation of Increased Tumor Intrinsic Glycolytic Activity with Resistance to Adoptive T Cell Therapy

Tina Cascone1, Jodi Alicia McKenzie1, Rina Mbofung1, Simone Punt1, Zhe Wang1, Chunyu Xu1, Leila Williams1, Zhiqiang Wang1, Christopher Bristow1, Alessandro Carugo1, Michael Peoples1, Lerong Li1, Tatiana Karpinets1, Shruti Malu1, Caitlin Creasy1, Sara Leahey1, Jiong Chen1, Chantale Bernatchez1, Y. N. Vashisht Gopal1, Timothy P. Heffernan1, Jianhua Hu1, Jing Wang1, Rodabe N. Amaria1, Levi A. Garraway2, Ignacio I. Wistuba1, Scott E. Woodman1, Jason Roszik1, R. Eric Davis1, Michael A. Davies1, John V. Heymach1, Patrick Hwu1, Weiyi Peng1

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA2Dana-Farber Cancer Institute, Boston, MA, USA

Tumor microenvironment | Adoptive immunotherapy | Metabolism | Immune suppression | T cell

O29

Mechanisms of Resistance to Immunotherapy

A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance

Jason Williams1, Shuyin Li1, Thomas Gajewski1, Haochu Huang1

1University of Chicago, Chicago, IL, USA

Immune tolerance | Antigen presenting cells | Tumor microenvironment | Checkpoint blockade | T cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Immune suppression

O30

Microbiome

Diversity and composition of the gut microbiome influences responses to anti-PD1-therapy through beneficial changes in innate and adaptive immunity

Vancheswaran Gopalakrishnan1, Christine Spencer1, Luigi Nezi1, Alexandre Reuben1, Miles Andrews1, Tatiana Karpinets1, Diego Vicente1, Peter Prieto2, Kristi Hoffman1, Spencer Wei1, Alexandria Cogdill1, Erick Riquelme Sanchez1, Florencia McAllister1, Michael Wong1, Michael Davies1, Alexander Lazar1, Jeffrey Gershenwald1, Nadim Ajami3, Zachary Cooper4, Joseph Petrosino3, Carrie Daniel-MacDougall1, Michael Tetzlaff1, James Allison1, Padmanee Sharma1, Robert Jenq1, Jennifer Wargo1

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA2University of Rochester Medical Center, Rochester, NY, USA3Baylor College of Medicine, Houston, TX, USA4MedImmune, Gaithersburg, MD, USA

Microbiome | Tumor microenvironment | Checkpoint blockade | Clinical study | Biomarkers | T cell

O31

Oncolytic Viruses and Intratumoral Therapies

Preclinical characterization of a novel STING agonist, MK-1454

Saso Cemerski1, Michael Altman1, Madhavi Bandi1, Wonsuk Chang2, Yiping Chen1, Long Cui1, Jared Cumming1, Lauren Dorosh1, Lauren Flateland1, Yanhong Ma1, Sarah Javaid1, Thu Ho3, Johnny Kopinja1, Jason Laskey1, Ellen Minnihan1, Laura Price3, Robin Mogg3, Gregory O'Donnell3, Bo-Sheng Pan1, Samanthi Perera1, Jennifer Piesvaux1, Jeremy Presland1, Larissa Rakhilina1, Gottfried Schroeder1, Michael Slavonic1, Steven Smock1, Benjamin Wesley Trotter1, Daniel Wyss2, Qing Zhao4, Shuxia Zhao1, Svetlana Sadekova5, Ying Yu5, Anuradha Khilnani4, Archie Tse4

1Merck Research Laboratories, Boston, MA, USA2Merck Research Laboratories, Kenilworth, NJ, USA3Merck Research Laboratories, West Point, PA, USA4Merck Research Laboratories, Rahway, NJ, USA5Merck Research Laboratories, Palo Alto, CA, USA

Antigen presenting cells | Myeloid cells | T cell | Clinical trial | Cytokine | Immune adjuvant | Gene expression | Monocyte/Macrophage | Tumor microenvironment | Checkpoint blockade

O32

Other

Phase 1 trial of CA-170, a first-in-class, orally available, small molecule immune checkpoint inhibitor (ICI) dually targeting PD-L1 and VISTA, in patients with advanced solid tumors or lymphomas

Yung Jue Bang1, John Powderly2, Manish Patel3, Kyu Pyo Kim4, James Lee5, Joshua Brody6, Javier Garcia-Corbacho7, Sun Young Rha8, Funda Meric-Bernstam9, Erika Hamilton10, Santiago Ponce Aix11, Radhakrishnan Ramchandren12, Jeffrey Sosman13, Myung Ju Ahn14, Mario Snozl15, Gerald Falchook16, Marta Gil Martin17, Hongwei Wang18, Lisa Adams18, Christopher Caldwell18, Adam Lazorchak18, Timothy Wyant18, Anna Ma18, David Tuck18, Adil Daud19

1Seoul National University Hospital, Seoul, Republic of Korea2Carolina BioOncology, Huntersville, NC, USA3Florida Cancer Specialists & Research Institute, Sarasota, FL, USA4Asan Medical Center, Seoul, Republic of Korea5University of Pittsburgh School of Medicine UPMC Cancer Pavilion, Pittsburgh, PA, USA6Icahn School of Medicine at Mount Sinai, New York, NY, USA7Hospital Clinic i Provincial, Barcelona, Spain8Yonsei University Health System - Severance Hospital, Seoul, Republic of Korea9UT MD Anderson Cancer Center, Houston, TX, USA10Sarah Cannon Research Institute - TN, Nashville, TN, USA11Hospital Universitario 12 de Octubre, Madrid, Spain12Karmanos Cancer Institute, Detroit, MI, USA13Northwestern University Research, Evanston, IL, USA14Samsung Medical Center, Seoul, Republic of Korea15Smilow Cancer Center, New Haven, CT, USA16Sarah Cannon Research Institute at HealthONE, Denver, CO, USA17Catalan Institute of Oncology, Bacelona, Spain18Curis Inc., Lexington, MA, USA19University of California San Francisco (UCSF), San Francisco, CA, USA

Checkpoint blockade | Clinical study | Targeted therapy | Clinical trial | T cell

O33

PHYSICIAN/NURSE/PHARM: irAE Management: Clinical Care and Best Practices

Variance from evidence-based management of immune-related adverse events among healthcare providers: analysis of an online management decision tool

Krista Marcello1, Kevin L. Obholz1, Timothy A. Quill1, Jeffrey S. Weber2

1Clinical Care Options, LLC, Reston, VA, USA2NYU Langone Medical Center, New York, NY, USA

Checkpoint blockade | Immune toxicity

O34

Tumor Microenvironment (Mechanisms and Therapies)

Cross-dressed dendritic cells drive anti-tumor immunity

Brendan MacNabb1, Douglas Kline1, Justin Kline1

1The University of Chicago, Chicago, IL, USA

Dendritic cell | Antigen presenting cells | Tumor microenvironment | Tumor antigens | Solid tumors